Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Change in Account Payables (2016 - 2025)

Marimed (MRMD) has disclosed Change in Account Payables for 15 consecutive years, with $23000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 96.25% to $23000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.7 million, a 157.58% decrease, with the full-year FY2024 number at $4.2 million, up 76.34% from a year prior.
  • Change in Account Payables was $23000.0 for Q3 2025 at Marimed, up from -$2.8 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.2 million in Q1 2022 to a low of -$2.8 million in Q2 2025.
  • A 5-year average of $263421.1 and a median of $399000.0 in 2021 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: skyrocketed 4786.69% in 2021, then plummeted 278.92% in 2022.
  • Marimed's Change in Account Payables stood at -$2.0 million in 2021, then soared by 32.51% to -$1.3 million in 2022, then soared by 137.7% to $507000.0 in 2023, then crashed by 106.31% to -$32000.0 in 2024, then soared by 171.88% to $23000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Change in Account Payables are $23000.0 (Q3 2025), -$2.8 million (Q2 2025), and $86000.0 (Q1 2025).